ArticleImmunity & ageing : I & A2020
"The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection?
Article in Immunity & ageing : I & A, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Viral reactivations and co-infections in COVID-19 patients: a systematic review.BMC infectious diseases · 2023Pooled it
- Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Pooled it
- Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.The Journal of infectious diseases · 2026Trial
- Clinical Features and Outcomes of Patients with Full Spectrum of COVID-19 Severity and Concomitant Herpesvirus Reactivation.Microorganisms · 2025Article
- SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms.International journal of molecular sciences · 2024Review
- CMV Retinitis in the Context of SARS-CoV-2 Infection: A Case Study and Comprehensive Review of Viral Interactions.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease.International journal of molecular sciences · 2024Review
- Loop-mediated isothermal amplification assay for screening congenital cytomegalovirus infection in newborns.Applied microbiology and biotechnology · 2023Article
- Accelerated T-Cell Immunosenescence in Cytomegalovirus-Seropositive Individuals After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.The Journal of infectious diseases · 2023Article
- Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV.Vaccines · 2023Article
- Human Cytomegalovirus Infection of Epithelial Cells Increases SARS-CoV-2 Superinfection by Upregulating the ACE2 Receptor.The Journal of infectious diseases · 2023Article
- Risk Factors for One-Year Mortality in Hospitalized Adults with Severe COVID-19.Aging and disease · 2023Article
- Modifiable contributing factors to COVID-19: A comprehensive review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2023Review
- Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.Frontiers in immunology · 2023Article
- Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- CMV Infection Following mRNA SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.Transplantation direct · 2022Article
- Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection.Open forum infectious diseases · 2022Article
- A case-series of six autopsy cases of COVID-19 including three cases of cytomegalovirus coinfection.Pathology international · 2022Article
- Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic represents one of the greatest infectious challenges to humanity in recent history. One of the striking features of infection is the heterogeneous clinical response with worse outcomes observed in older patients and those with underlying health conditions. To date the potential impact of previous infection history has been poorly investigated as a potential determinant of risk. Cytomegalovirus (CMV), a persistent herpesvirus infection whose prevalence increases with age, is a major modulator of immune function and several observations suggest that infection might act to influence clinical outcome following SARS-CoV-2 infection. In particular, CMV is associated with the acceleration of immune senescence and has been linked to a range of cardiovascular and metabolic disorders. This review addresses mechanisms by which cytomegalovirus infection may act to worsen the clinical outcome of SARS-CoV-2 infection, discusses how these potential links could be investigated, and assesses the potential significance of any findings that emerge.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.